Biosimilars in IBD: Will it benefit to patients, physicians or the health care system?

Lorant Gonczi, Akos Ilias, Zsuzsanna Kurti, P. Lakatos

Research output: Article

2 Citations (Scopus)

Abstract

The introduction of biological drugs has revolutionized the management of inflammatory bowel diseases (IBD), however, the increasing financial burden of biologicals on the health care system is alarming. Biosimilars are considered to be equivalent to the reference medicinal product (RMP) in terms of pharmacokinetic properties, clinical effectiveness and safety. CT-P13 infliximab was the first biosimilar to be approved by the regulatory authorities EMA and US FDA, and others are becoming increasingly available as patents expire on the RMP. Emerging data suggests that one-way switching from the RMP to an approved biosimilar is safe and acceptable, however data on multiple-switching, reversed switching, or cross-switching between biosimilars is scarce. Accumulating data on biosimilars led to an increased acceptance amongst physicians and their use can be expected to offer increased availability for patients, and also better control of economic sustainability. This review discusses the available data on clinical efficacy and safety of approved biosimilar agents, and assesses the current impact and future perspectives of biosimilars on the health care system.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalCurrent pharmaceutical design
Volume25
Issue number1
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Delivery of Health Care
Physicians
Safety
Patents
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Biosimilars in IBD : Will it benefit to patients, physicians or the health care system? / Gonczi, Lorant; Ilias, Akos; Kurti, Zsuzsanna; Lakatos, P.

In: Current pharmaceutical design, Vol. 25, No. 1, 01.01.2019, p. 13-18.

Research output: Article

Gonczi, Lorant ; Ilias, Akos ; Kurti, Zsuzsanna ; Lakatos, P. / Biosimilars in IBD : Will it benefit to patients, physicians or the health care system?. In: Current pharmaceutical design. 2019 ; Vol. 25, No. 1. pp. 13-18.
@article{8234d84517e440b99d059e41f13c0d53,
title = "Biosimilars in IBD: Will it benefit to patients, physicians or the health care system?",
abstract = "The introduction of biological drugs has revolutionized the management of inflammatory bowel diseases (IBD), however, the increasing financial burden of biologicals on the health care system is alarming. Biosimilars are considered to be equivalent to the reference medicinal product (RMP) in terms of pharmacokinetic properties, clinical effectiveness and safety. CT-P13 infliximab was the first biosimilar to be approved by the regulatory authorities EMA and US FDA, and others are becoming increasingly available as patents expire on the RMP. Emerging data suggests that one-way switching from the RMP to an approved biosimilar is safe and acceptable, however data on multiple-switching, reversed switching, or cross-switching between biosimilars is scarce. Accumulating data on biosimilars led to an increased acceptance amongst physicians and their use can be expected to offer increased availability for patients, and also better control of economic sustainability. This review discusses the available data on clinical efficacy and safety of approved biosimilar agents, and assesses the current impact and future perspectives of biosimilars on the health care system.",
keywords = "Biosimilars, Cost-effectiveness, Crohn’s disease, Infliximab, Switch, Ulcerative colitis",
author = "Lorant Gonczi and Akos Ilias and Zsuzsanna Kurti and P. Lakatos",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1381612825666190312112900",
language = "English",
volume = "25",
pages = "13--18",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Biosimilars in IBD

T2 - Will it benefit to patients, physicians or the health care system?

AU - Gonczi, Lorant

AU - Ilias, Akos

AU - Kurti, Zsuzsanna

AU - Lakatos, P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The introduction of biological drugs has revolutionized the management of inflammatory bowel diseases (IBD), however, the increasing financial burden of biologicals on the health care system is alarming. Biosimilars are considered to be equivalent to the reference medicinal product (RMP) in terms of pharmacokinetic properties, clinical effectiveness and safety. CT-P13 infliximab was the first biosimilar to be approved by the regulatory authorities EMA and US FDA, and others are becoming increasingly available as patents expire on the RMP. Emerging data suggests that one-way switching from the RMP to an approved biosimilar is safe and acceptable, however data on multiple-switching, reversed switching, or cross-switching between biosimilars is scarce. Accumulating data on biosimilars led to an increased acceptance amongst physicians and their use can be expected to offer increased availability for patients, and also better control of economic sustainability. This review discusses the available data on clinical efficacy and safety of approved biosimilar agents, and assesses the current impact and future perspectives of biosimilars on the health care system.

AB - The introduction of biological drugs has revolutionized the management of inflammatory bowel diseases (IBD), however, the increasing financial burden of biologicals on the health care system is alarming. Biosimilars are considered to be equivalent to the reference medicinal product (RMP) in terms of pharmacokinetic properties, clinical effectiveness and safety. CT-P13 infliximab was the first biosimilar to be approved by the regulatory authorities EMA and US FDA, and others are becoming increasingly available as patents expire on the RMP. Emerging data suggests that one-way switching from the RMP to an approved biosimilar is safe and acceptable, however data on multiple-switching, reversed switching, or cross-switching between biosimilars is scarce. Accumulating data on biosimilars led to an increased acceptance amongst physicians and their use can be expected to offer increased availability for patients, and also better control of economic sustainability. This review discusses the available data on clinical efficacy and safety of approved biosimilar agents, and assesses the current impact and future perspectives of biosimilars on the health care system.

KW - Biosimilars

KW - Cost-effectiveness

KW - Crohn’s disease

KW - Infliximab

KW - Switch

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85068141568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068141568&partnerID=8YFLogxK

U2 - 10.2174/1381612825666190312112900

DO - 10.2174/1381612825666190312112900

M3 - Article

C2 - 30864504

AN - SCOPUS:85068141568

VL - 25

SP - 13

EP - 18

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 1

ER -